

Improving Medicare's end-stage renal disease prospective payment system

Nancy Ray and Andy Johnson

March 6, 2020

Presentation overview

- Background on ESRD PPS
- Overview of how Medicare pays for new dialysis drugs
- Policy option: Eliminating the transitional drug add-on payment adjustment (TDAPA) for new ESRD drugs in an existing ESRD functional category
- Overview of how Medicare pays dialysis facilities that are low-volume and located in rural areas
- Policy option: Replacing the low-volume and rural payment adjustments with a single payment adjustment that targets low-volume and isolated facilities
- Chairman's draft recommendations

ESRD PPS implemented in 2011

- Expanded payment bundle includes ESRD-related drugs and laboratory tests that were previously paid separately
- To implement the bundle, CMS categorized ESRD drugs in *11 ESRD functional categories*
- Facility-level adjustments: low volume, rural location, and labor costs
- Patient-level adjustments: Age, body mass index, body surface area, time since dialysis onset, acute and chronic comorbidities
- Added on to the base rate: Payments for self-dialysis training and outliers; transitional drug add-on payments for calcimimetics

Overview of how Medicare pays for new ESRD drugs under a TDAPA policy

New ESRD-related drugs that:	Are <i>not</i> in an existing functional category	Are in an existing functional category
Initial policy year	2016	2020
How is payment set?	ASP	ASP
Length of add-on payment period	At least 2 years	2 calendar years
Is the ESRD PPS base rate updated at end of add-on payment period?	Yes	No

Issues with the TDAPA policy for new drugs in an existing ESRD functional category

- Paying separately for drugs in a functional category temporarily unbundles the ESRD bundle
 - Inhibits competition among drugs in the same functional category
 - Fails to provide an incentive to reduce new drug launch prices
 - Prior to TDAPA, an ESA was introduced directly into the bundle in 2015: One-quarter of patients switched in the first year and ESA costs declined
- TDAPA payment is duplicative of bundled payment
 - TDAPA covers full cost of the new drug in addition to the payment for the functional category already included in the base rate
 - Paying TDAPA on a per unit basis in addition to the bundle increases the incentive to provide TDAPA-covered drugs and may promote their overuse

Policy option: Eliminate the TDAPA for new ESRD drugs in an existing functional category

- At market entry, new ESRD drugs in an existing functional category would be included in the payment bundle
- No concurrent update to the base payment rate
- Monitor payment adequacy of Medicare's ESRD payments to identify need for rebasing
- Maintain the TDAPA for new dialysis drugs that do not fit into an ESRD functional category and for calcimimetics

Payment for low-volume and isolated facilities

- Why modify current low-volume and rural payment adjustment factors?
 - Concern about Medicare financial performance of low-volume dialysis facilities necessary to ensure beneficiary access to care
 - Design of low-volume payment adjustment (LVPA) and rural payment adjustment does not meet Commission principles on rural payment adjustments (2012)
 - Protect low-volume *and* isolated facilities critical to beneficiary access
 - Adjustment magnitude should be empirically justified
 - Adjustments should encourage provider efficiency

LVPA does not target isolated and low-volume facilities

- LVPA criteria:
 - Base rate of LVPA facilities is increased by 23.9 percent
 - Furnished less than 4,000 treatments in each of the 3 years before the payment year in question
 - Distance to nearest facility only considered for facilities under common ownership and within 5 miles of each other
- Concerns with design of LVPA:
 - Single threshold may encourage limiting treatment or inaccurate reporting
 - Does not address higher costs at facilities with 4,000 to 6,000 treatments
 - Does not target isolated facilities, 40 percent within 5 miles of another facility


Rural adjustment does not target low-volume and isolated facilities

- In 2017, 18 percent of facilities received a 0.8 percent increase to their base rate for being located in a rural area
- Concerns with rural adjustment
 - About 30 percent of rural facilities were located within 5 miles of the nearest facility
 - About 50 percent of rural facilities were higher-volume, furnishing more than 6,000 treatments

Policy option: Replace the current low volume and rural payment adjustments with a single adjustment

- The low-volume and isolated (LVI) payment adjustment would target facilities that are both low-volume and isolated
- To model the LVI adjustment:
 - Facility must be isolated
 - Farther than 5 miles from nearest facility (regardless of ownership)
 - Facility must exhibit low volume over three preceding years
 - Provide up to 6,000 treatments per year

Policy option would redistribute some payments from non-isolated and high-volume facilities



Discussion

- Chairman's draft recommendations to:
 - Eliminate the TDAPA for new ESRD drugs in an existing ESRD functional category
 - Replace the current LVPA and the rural adjustment with a single facility-level adjustment for low-volume and isolated facilities
- Analyses will be included in a June 2020 chapter on ESRD PPS design issues